ASCO 2025: Adding niraparib to standard treatment may slow cancer growth for some patients with mCSPC
Results from the international phase 3 AMPLTUDE clinical trial found that adding niraparib to abiraterone…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Bioactive soluble recombinant mouse LIGHT protein promotes effective tumour immune cell infiltration delaying tumour growth
LIGHT (TNFSF14), a protein within the tumour necrosis factor (TNF) superfamily, signals through two distinct receptors:…
ESMO Breast 2025: Immunotherapy research shows promising results for patients with advanced HER2-positive breast cancer
Results from the DIAmOND clinical trial have shown that adding dual immunotherapy to existing treatments…
ASCO 2025: Addition of lurbinectedin to first-line maintenance treatment for small cell lung cancer prolongs survival, according to phase 3 trial
Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers, and most patients…
ASCO 2025: Dual-target CAR T-cell therapy slows growth of aggressive brain cancer
A dual-target CAR T cell therapy approach shows promise for slowing tumour growth in glioblastoma. Tumours became…
ASCO 2025: Atezolizumab chemo combo leads to improved survival in deficient mismatch repair colon cancer
The results of an international phase 3 clinical trial sponsored by the National Cancer Institute,…
ASCO 2025: Rusfertide shows promise for polycythemia vera treatment
Results from the Phase 3, randomised, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia…
ASCO 2025: Switch to camizestrant after liquid biopsy detection of breast cancer recurrence improves outcomes
A large prospective, randomised clinical trial in patients with advanced breast cancer has found that…
ASCO 2025: Exercise programme may lower risk of recurrence and death for some colon cancer survivors
New study results show that a structured exercise programme following surgery and adjuvant chemotherapy reduced…
ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers
Results from an international phase 3 clinical trial found that treating stage II, III, and…